^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
alveltamig (ZG006)
i
Other names: ZG006
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Suzhou Zelgen
Drug class:
CD3 agonist, DLL3 inhibitor
Related drugs:
2d
Study of ZGGS34 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=400, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
New P1/2 trial
|
alveltamig (ZG006)
17d
Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer (clinicaltrials.gov)
P1, N=100, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
New P1 trial • Checkpoint inhibition
|
Hetronifly (serplulimab) • alveltamig (ZG006)
17d
ZG006-002: Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer (clinicaltrials.gov)
P1/2, N=265, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | N=105 --> 265
Enrollment change
|
alveltamig (ZG006)
2ms
Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer (clinicaltrials.gov)
P3, N=420, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
New P3 trial
|
topotecan • alveltamig (ZG006)
5ms
ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma (clinicaltrials.gov)
P1/2, N=350, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
New P1/2 trial
|
alveltamig (ZG006) • nilvanstomig (ZG005)
6ms
Study of ZG006 in Participants With Neuroendocrine Prostate Cancer (clinicaltrials.gov)
P2, N=60, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
New P2 trial
|
alveltamig (ZG006)
7ms
A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer (clinicaltrials.gov)
P1, N=30, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting --> Recruiting | Initiation date: Dec 2024 --> Mar 2025
Enrollment open • Trial initiation date
|
alveltamig (ZG006)
12ms
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer (clinicaltrials.gov)
P1/2, N=105, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting --> Recruiting | Initiation date: Jun 2024 --> Sep 2024
Enrollment open • Trial initiation date • Metastases
|
alveltamig (ZG006)
12ms
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma. (clinicaltrials.gov)
P1/2, N=78, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
alveltamig (ZG006)
1year
A Phase 1 Dose Escalation Study of ZG006 in Patients with Small Cell Lung Cancer (clinicaltrials.gov)
P1, N=30, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
New P1 trial
|
alveltamig (ZG006)
over1year
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma. (clinicaltrials.gov)
P1/2, N=78, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
New P1/2 trial • Metastases
|
alveltamig (ZG006)
almost2years
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer (clinicaltrials.gov)
P1/2, N=105, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
New P1/2 trial
|
alveltamig (ZG006)
Share via
